On October 2, 2015 Incyte Corporation (Nasdaq:INCY) reported that new data from its investigational immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 30th Anniversary Annual Meeting & Associated Programs, November 4–8, 2015 at the Gaylord National Resort & Convention Center in National Harbor, MD (Press release, Incyte, OCT 2, 2015, View Source;p=RssLanding&cat=news&id=2092622 [SID:1234507633]). Safety and efficacy data from a Phase 1/2 study evaluating epacadostat, Incyte’s selective IDO1 inhibitor, in combination with pembrolizumab, an anti-PD-1 therapy, will be presented as a late-breaking oral presentation. Additionally, data from INCB50465, Incyte’s selective PI3Kδ inhibitor, will be presented as a poster.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased that data for both epacadostat and INCB50465 have been selected for presentation at the SITC (Free SITC Whitepaper) Annual Meeting next month," stated Hervé Hoppenot, President and Chief Executive Officer of Incyte. "We look forward to sharing the progress of our immuno-oncology portfolio, which reflects our commitment to developing new medicines that may improve the lives of patients with cancer."
Incyte abstracts to be presented at SITC (Free SITC Whitepaper) include:
Preliminary results from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with selected advanced cancers (Abstract #142)
Friday, November 6, 2015, 12:00-12:15 PM EST
Maryland Ballroom
Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents (Poster #394)
Friday, November 6, 2015, 6:15–7:30 PM ET and Saturday, November 7, 2015,
12:45–2:00 PM EST
Prince George’s Exhibition Hall A
Full session details and data presentation listings for SITC (Free SITC Whitepaper) 2015 can be found at: View Source
About Epacadostat
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been shown to induce regulatory T cell generation and activation, and allow tumors to escape immune surveillance. Epacadostat is an orally bioavailable small molecule inhibitor of IDO1 that has nanomolar potency in both biochemical and cellular assays and has demonstrated potent activity in enhancing T lymphocyte, dendritic cell and natural killer cell responses in vitro, with a high degree of selectivity. Epacadostat has shown proof-of-concept clinical data in patients with unresectable or metastatic melanoma in combination with the CTLA-4 inhibitor ipilimumab, and is currently in four proof-of-concept clinical trials with PD-1 and PD-L1 immune checkpoint inhibitors in a variety of cancer histologies.
About Pembrolizumab
Pembrolizumab, marketed in the U.S. by Merck under the brand name KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.